RxDoctor Payments Data

Jullie Macasero-Navarro

Nurse Practitioner · Laredo, TXNPI 1811244056

Payments from drug & device makers

$351in general payments, 2019–2025

Across 18 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$164
  • Amgen$69
  • Novo Nordisk$27
  • Merck$24
  • Novartis$19
  • Dexcom, Inc.$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$351 in reported general payments places this provider in the 65th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$368
Medicare patients
12
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide155$230,055
JardianceEmpagliflozin81$110,408
MounjaroTirzepatide69$97,833
FarxigaDapagliflozin Propanediol69$84,953
JanumetSitagliptin Phos/Metformin Hcl33$34,039
Praluent PenAlirocumab26$33,954
Tresiba Flextouch U-100Insulin Degludec52$32,582
SynjardyEmpagliflozin/Metformin Hcl23$31,081
KerendiaFinerenone15$21,671
TradjentaLinagliptin20$20,671
Xigduo XrDapaglifloz Propaned/Metformin23$19,504
JanuviaSitagliptin Phosphate16$19,269
Repatha SureclickEvolocumab21$18,430
VascepaIcosapent Ethyl23$12,845
Omega-3 Acid Ethyl Esters42$5,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$27$230,055155 claims
Lilly USA, LLCMounjaro$16$97,83369 claims
MerckJanumet, Januvia$24$53,30849 claims
BayerKerendia$164$21,67115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →